Marketing Authorization of Pharmaceutical Products with Special Reference to Multisource (Generic) Products: A Manual for Drug Regulatory Authorities - Regulatory Support Series No. 005
(1998; 213 pages)
Table of Contents
View the documentPREFACE
View the documentI. INTRODUCTION
Open this folder and view contentsII. PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL
Close this folderIII. OPERATING ACTIVITIES
View the documentA. Transparency
View the documentB. Policies
View the documentC. Administrative procedures
View the documentD. Guidelines for applicants
View the documentE. Model application form
View the documentF. Communication among departments within the DRA
View the documentG. Relationship of evaluators with GMP inspectors
View the documentH. Relationship of evaluators with the quality control laboratories
View the documentI. Functional relationship of the evaluators with the expert advisory body
View the documentJ. Relationship of evaluators with the pharmaceutical industry and confidentiality of data
View the documentK. Meetings with applicants
View the documentL. Procedures for appeals
View the documentM. Collaboration with other DRAs
View the documentN. Collaboration with WHO
View the documentO. Use of external experts as evaluators
View the documentP. Timeframes for processing of applications
View the documentQ. Publication of marketing authorization decisions
Open this folder and view contentsIV. REVIEW OF APPLICATIONS FOR MARKETING AUTHORIZATION OF MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS
View the documentV. ISSUE OF WRITTEN MARKETING AUTHORIZATION
View the documentVI. VARIATIONS
View the documentVII. PERIODIC REVIEWS
View the documentVIII. SUSPENSION AND REVOCATION OF MARKETING AUTHORIZATION
View the documentGLOSSARY
View the documentABBREVIATIONS
View the documentREFERENCES
Open this folder and view contentsANNEXES
 

C. Administrative procedures

Administrative procedures should be documented and published. Correspondence and data are far less likely to go astray when clear procedures are in place. It is particularly important that all DRA staff have copies of administrative documentation and understand their own role in the procedures.

If pharmaceutical companies have access to the written administrative procedures, they will better understand how to submit applications, whom to contact when they have questions, and how to respond on receipt of correspondence. When they have an inquiry, they can ask more precise and sensible questions. The industry and DRA staff should be informed of the appropriate lines of communication.

to previous section to next section
 

Last updated: May 3, 2013